Cargando…
2334. The effectiveness of bivalent COVID-19 booster among patients with hematologic malignancies
BACKGROUND: Patients with hematologic malignancies remain at higher risk for developing severe SARS-CoV-2 infections and have reduced immune responses to vaccines. METHODS: A prospective observational study was conducted at Brigham and Women’s Hospital and Dana-Farber Cancer Institute from January 2...
Autores principales: | Aleissa, Muneerah M, Davey, Sonya, Rooks, Rebecca, Izaguirre, Natalie E, Yates, Bridget, Kanwal, Urwah, Baden, Lindsey R, Issa, Nicolas C, Sherman, Amy C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677953/ http://dx.doi.org/10.1093/ofid/ofad500.1956 |
Ejemplares similares
-
2707. Complications of Babesiosis in Immunocompromised and Asplenic/Hyposplenic Patients
por: Harris, Courtney E, et al.
Publicado: (2023) -
SARS-CoV-2 Vaccine-Induced Immune Responses Among Hematopoietic Stem Cell Transplant Recipients
por: Kokogho, Afoke, et al.
Publicado: (2023) -
Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Immunogenicity among Chimeric Antigen Receptor T Cell Therapy Recipients
por: Aleissa, Muneerah M., et al.
Publicado: (2023) -
A Bivalent Omicron-Containing Booster Vaccine against Covid-19
por: Chalkias, Spyros, et al.
Publicado: (2022) -
Durability of Bivalent Boosters against Omicron Subvariants
por: Lin, Dan-Yu, et al.
Publicado: (2023)